Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Lattice Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma
NCT07335380Phase 1Not yet recruiting
- Sponsor
- NYU Langone Health
- Start
- Apr 2026
- Primary completion
- Mar 2031
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab, carboplatin and paclitaxel in oral cavity squamous cell carcinoma (OCSCC) (2 arms), sponsored by NYU Langone Health. Primary endpoint: Maximum Tolerated Dose. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT07335380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07335380.